SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2013 / Cilt: 43 - Sayı: 1

Insulin resistance impairs response to doxazosin therapy in men with benign prostatic hyperplasia

Cevdet Serkan GÖKKAYA
Cüneyt ÖZDEN
Çetin Volkan ÖZTEKİN
Ali MEMİŞ
Binhan Kağan AKTAŞ
Emin ÖZTÜRK
Pages
1–5
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The presence of IR should be kept in mind in patients refractory to doxazosin therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:To evaluate the effects of insulin resistance (IR) on outcomes of doxazosin treatment for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).
📊
Key Findings & Data:Materials and methods: This prospective study included 64 patients with LUTS due to BPH.
💡
Conclusion & Impact:The presence of IR should be kept in mind in patients refractory to doxazosin therapy.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Key words: Insulin resistance · benign prostatic hyperplasia · doxazosin

Abstract

To evaluate the effects of insulin resistance (IR) on outcomes of doxazosin treatment for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Materials and methods: This prospective study included 64 patients with LUTS due to BPH. LUTS were evaluated using the international prostate symptom score (IPSS) and maximum flow rate (Qmax) in uroflowmetry. Diagnosis of IR was achieved using homeostasis model assessment (HOMA) score and patients were grouped with respect to absence (group 1, n = 44) or presence (group 2, n = 20) of IR. Patients were evaluated before and after 3 months of daily doxazosin therapy (4 mg extended release tablet). Results: Doxazosin significantly improved the IPSS and Qmax in group 1 (P = 0.04 and P = 0.008, respectively). In group 2, doxazosin treatment had no significant therapeutic effect on mean IPSS and Qmax (P = 0.116 and P = 0.477, respectively). On the other hand, doxazosin significantly improved mean HOMA scores of patients with IR (P = 0.015). Conclusion: IR impairs response to doxazosin treatment for LUTS due to BPH. The presence of IR should be kept in mind in patients refractory to doxazosin therapy.

Özet

To evaluate the effects of insulin resistance (IR) on outcomes of doxazosin treatment for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Materials and methods: This prospective study included 64 patients with LUTS due to BPH. LUTS were evaluated using the international prostate symptom score (IPSS) and maximum flow rate (Qmax) in uroflowmetry. Diagnosis of IR was achieved using homeostasis model assessment (HOMA) score and patients were grouped with respect to absence (group 1, n = 44) or presence (group 2, n = 20) of IR. Patients were evaluated before and after 3 months of daily doxazosin therapy (4 mg extended release tablet). Results: Doxazosin significantly improved the IPSS and Qmax in group 1 (P = 0.04 and P = 0.008, respectively). In group 2, doxazosin treatment had no significant therapeutic effect on mean IPSS and Qmax (P = 0.116 and P = 0.477, respectively). On the other hand, doxazosin significantly improved mean HOMA scores of patients with IR (P = 0.015). Conclusion: IR impairs response to doxazosin treatment for LUTS due to BPH. The presence of IR should be kept in mind in patients refractory to doxazosin therapy.

🔖

Cite This Article

GÖKKAYA, C. S., ÖZDEN, C., ÖZTEKİN, Ç. V., MEMİŞ, A., AKTAŞ, B. K., ÖZTÜRK, E. (2022). Insulin resistance impairs response to doxazosin therapy in men with benign prostatic hyperplasia. Turkish Journal of Medical Sciences, Cilt: 43 - Sayı: 1, 1–5. https://ajindex.com/articles/611022

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Parsons JK. Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. Curr Bladder 2010; 5: 212–8.
  2. Robertson C, Link CL, Onel E, Mazzetta C, Keech M, Hobbs R et al. The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies. BJU Int 2007; 99: 347–54. Kaplan SA. Current role of alpha-blockers in the treatment of benign prostatic hyperplasia. BJU Int 2008; 102 [Suppl 2]: 3–7.
  3. Kaplan SA, Holtgrewe HL, Bruskewitz R, Saltzman B, Mobley D, Narayan P et al. Proscar Long-Term Efficacy and Safety Study Group. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology 2001; 57: 1073–7. Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am 2009; 36: 403–5.
  4. Marker PC, Donjacour AA, Dahiya R, Cunha GR. Hormonal, cellular, and molecular control of prostatic development. Dev Biol 2003; 15: 165–74. Geller J. Overview of benign prostatic hypertrophy. Urology 1989; 34 [Suppl 4]: 57–63.
  5. Moul S, McVary KT. Lower urinary tract symptoms, obesity and the metabolic syndrome. Curr Opin Urol 2010; 20: 7–12.
  6. Nandeesha H, Koner BC, Dorairajan LN, Sen SK. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta 2006; 370: 89–93. Lebovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes 2001; 109 [Suppl 2]: 135–48.
  7. Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001; 39: 151–8.
  8. Hammarsten J, Damber JE, Karlsson M, Knutson T, Ljunggren O, Ohlsson C et al. Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2009; 12: 160–5.
  9. Ueshiba H, Miyachi Y. Effect of doxazosin on insulin resistance in hypertensive patients with obesity. Horm Metab Res 2003; 35: 532–6.
  10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–9.
  11. Şahin M, İnal BB, Öğreden Ş, Yiğit Ö, Aral H, Güvenen G. Metabolic profile and insulin resistance in patients with obstructive sleep apnea syndrome. Turk J Med Sci 2011; 41: 443–54.
  12. Ayvaz DNÇ, Kılınç FN, Paç FA, Çakal E. Anthropometric measurements and body composition analysis of obese adolesc